Brief: CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient With Cer-1236
July 31 (Reuters) - CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS DOSES SECOND ACUTE MYELOID LEUKEMIA PATIENT WITH CER-1236 Source text: ID:nGNXbZpbSK Further company coverage: CERO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List